Raloxifene Inhibits Bone Loss and Improves Bone Strength Through an Opg-independent Mechanism

Overview

Journal Endocrine

Specialty Endocrinology

Date 2010 Oct 22

PMID 20963556

Citations 5

Authors

Mei-zhu Yan

Yong Xu

Yun-Xia Gong

Jian-Min Liu

Shun-Yuan Lu

Lei Huang

Zhu-Gang Wang

Yong-Ju Zhao

Xiao-fen Pang

Affiliations

Soon will be listed here.

Abstract

The osteoblast-derived paracrine factor osteoprotegerin (OPG) is considered to play a key role in inhibition of osteoclast formation and activity. Recently, raloxifene, a nonsteroidal benzothiophene, was found to exert anti-resorptive effects via modulating OPG expression in osteoblasts. To explore whether raloxifene regulates bone metabolism via an OPG-dependant pathway in vivo, we investigated the effects of raloxifene on bone loss in Opg-deficient mice. The results show that bone mineral density and bone strength are increased in mice deficient for Opg after treatment with raloxifene for 30 days. Histomorphometric analysis shows that raloxifene can increase bone trabecular area and decrease the number of osteoclasts in Opg (-/-) mice. Moreover, raloxifene reduces Rankl transcription and serum level of Rankl, which is dramatically increased in Opg knockout mice. These results suggest that raloxifene-induced inhibition of bone resorption may be independent of Opg pathway in mice.

Citing Articles

Long-term and sequential treatment for osteoporosis.

Foessl I, Dimai H, Obermayer-Pietsch B Nat Rev Endocrinol. 2023; 19(9):520-533.

PMID: 37464088 DOI: 10.1038/s41574-023-00866-9.

Time and dose-dependent effects of Labisia pumila on the bone strength of postmenopausal osteoporosis rat model.

Effendy N, Abdullah S, Yunoh M, Shuid A BMC Complement Altern Med. 2015; 15:58.

PMID: 25887391 PMC: 4364645. DOI: 10.1186/s12906-015-0567-x.

Incorporation of raloxifene-impregnated allograft around orthopedic titanium implants impairs early fixation but improves new bone formation.

Hermansen L, Sorensen M, Barckman J, Bechtold J, Soballe K, Baas J Acta Orthop. 2014; 86(1):127-33.

PMID: 25175661 PMC: 4366660. DOI: 10.3109/17453674.2014.958808.

Cartilage Protective and Chondrogenic Capacity of WIN-34B, a New Herbal Agent, in the Collagenase-Induced Osteoarthritis Rabbit Model and in Progenitor Cells from Subchondral Bone.

Huh J, Park Y, Seo B, Lee J, Baek Y, Choi D Evid Based Complement Alternat Med. 2013; 2013:527561.

PMID: 23983790 PMC: 3747396. DOI: 10.1155/2013/527561.

Denosumab: mechanism of action and clinical outcomes.

Hanley D, Adachi J, Bell A, Brown V Int J Clin Pract. 2012; 66(12):1139-46.

PMID: 22967310 PMC: 3549483. DOI: 10.1111/ijcp.12022.

References

Bucay N, Sarosi I, Dunstan C, Morony S, Tarpley J, Capparelli C . osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 1998; 12(9):1260-8. PMC: 316769. DOI: 10.1101/gad.12.9.1260. View

Cheung J, Mak Y, Papaioannou S, Evans B, Fogelman I, Hampson G . Interleukin-6 (IL-6), IL-1, receptor activator of nuclear factor kappaB ligand (RANKL) and osteoprotegerin production by human osteoblastic cells: comparison of the effects of 17-beta oestradiol and raloxifene. J Endocrinol. 2003; 177(3):423-33. DOI: 10.1677/joe.0.1770423. View

Ramalho A, Couttet P, Baudoin C, Morieux C, Graulet A, de Vernejoul M . Estradiol and raloxifene decrease the formation of multinucleate cells in human bone marrow cultures. Eur Cytokine Netw. 2002; 13(1):39-45. View

Bord S, Horner A, Beavan S, Compston J . Estrogen receptors alpha and beta are differentially expressed in developing human bone. J Clin Endocrinol Metab. 2001; 86(5):2309-14. DOI: 10.1210/jcem.86.5.7513. View

Black L, Sato M, Rowley E, Magee D, Bekele A, Williams D . Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J Clin Invest. 1994; 93(1):63-9. PMC: 293730. DOI: 10.1172/JCI116985. View

Eriksen E, Colvard D, Berg N, Graham M, Mann K, Spelsberg T . Evidence of estrogen receptors in normal human osteoblast-like cells. Science. 1988; 241(4861):84-6. DOI: 10.1126/science.3388021. View

Vidal O, Kindblom L, Ohlsson C . Expression and localization of estrogen receptor-beta in murine and human bone. J Bone Miner Res. 1999; 14(6):923-9. DOI: 10.1359/jbmr.1999.14.6.923. View

Shevde N, Bendixen A, Dienger K, Pike J . Estrogens suppress RANK ligand-induced osteoclast differentiation via a stromal cell independent mechanism involving c-Jun repression. Proc Natl Acad Sci U S A. 2000; 97(14):7829-34. PMC: 16630. DOI: 10.1073/pnas.130200197. View

Messalli E, Mainini G, Scaffa C, Cafiero A, Salzillo P, Ragucci A . Raloxifene therapy interacts with serum osteoprotegerin in postmenopausal women. Maturitas. 2006; 56(1):38-44. DOI: 10.1016/j.maturitas.2006.05.007. View

10.

Viereck V, Grundker C, Blaschke S, Niederkleine B, Siggelkow H, Frosch K . Raloxifene concurrently stimulates osteoprotegerin and inhibits interleukin-6 production by human trabecular osteoblasts. J Clin Endocrinol Metab. 2003; 88(9):4206-13. DOI: 10.1210/jc.2002-021877. View

11.

Riggs B . Overview of osteoporosis. West J Med. 1991; 154(1):63-77. PMC: 1002677. View

12.

Rossouw J, Anderson G, Prentice R, LaCroix A, Kooperberg C, Stefanick M . Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002; 288(3):321-33. DOI: 10.1001/jama.288.3.321. View

13.

Mann V, Huber C, Kogianni G, Collins F, Noble B . The antioxidant effect of estrogen and Selective Estrogen Receptor Modulators in the inhibition of osteocyte apoptosis in vitro. Bone. 2006; 40(3):674-84. DOI: 10.1016/j.bone.2006.10.014. View

14.

Migliaccio S, Davis V, Gibson M, Gray T, Korach K . Estrogens modulate the responsiveness of osteoblast-like cells (ROS 17/2.8) stably transfected with estrogen receptor. Endocrinology. 1992; 130(5):2617-24. DOI: 10.1210/endo.130.5.1572285. View

15.

Parfitt A, Drezner M, Glorieux F, Kanis J, MALLUCHE H, Meunier P . Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res. 1987; 2(6):595-610. DOI: 10.1002/jbmr.5650020617. View

16.

Gianni W, Ricci A, Gazzaniga P, Brama M, Pietropaolo M, Votano S . Raloxifene modulates interleukin-6 and tumor necrosis factor-alpha synthesis in vivo: results from a pilot clinical study. J Clin Endocrinol Metab. 2004; 89(12):6097-9. DOI: 10.1210/jc.2004-0795. View

17.

Fournier B, Haring S, Kaye A, Somjen D . Stimulation of creatine kinase specific activity in human osteoblast and endometrial cells by estrogens and anti-estrogens and its modulation by calciotropic hormones. J Endocrinol. 1996; 150(2):275-85. DOI: 10.1677/joe.0.1500275. View

18.

Sato M, Rippy M, Bryant H . Raloxifene, tamoxifen, nafoxidine, or estrogen effects on reproductive and nonreproductive tissues in ovariectomized rats. FASEB J. 1996; 10(8):905-12. DOI: 10.1096/fasebj.10.8.8666168. View

19.

Taranta A, Brama M, Teti A, De Luca V, Scandurra R, Spera G . The selective estrogen receptor modulator raloxifene regulates osteoclast and osteoblast activity in vitro. Bone. 2002; 30(2):368-76. DOI: 10.1016/s8756-3282(01)00685-8. View

20.

Draper M, Flowers D, Huster W, Neild J, Harper K, Arnaud C . A controlled trial of raloxifene (LY139481) HCl: impact on bone turnover and serum lipid profile in healthy postmenopausal women. J Bone Miner Res. 1996; 11(6):835-42. DOI: 10.1002/jbmr.5650110615. View